Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
In this placebo‐controlled, blinded study, individuals with depression will participate in 2 experimental sessions approximately 4 weeks apart during which they will receive two of the following three interventions: 1) placebo, 2) low dose psilocybin (0.1 mg/kg), and 3) medium dose psilocybin (0.3 mg/kg).
Epistemonikos ID: 6a2ece00a33047ccece12fbb6f7b7bf191e8f78c
First added on: May 21, 2024